"instanceType","name","label","id","rationale","description","uuid:ID"
"StudyDesign","Study Design 1","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","9dee605d-d9ee-4376-917c-b9ac6bb49199"
